← Steven A. Rosenberg

Papers by Steven A. Rosenberg

Page 9 · newest first

401. Cytoreductive Surgery Before High Dose Interleukin-2 Based Therapy in Patients With Metastatic Renal Cell CarcinomaThe Journal of Urology · 1997
402. Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary MetastasesThe Journal of Experimental Medicine · 1997
403. Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cellsThe Journal of Immunology · 1997
404. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytesThe Journal of Immunology · 1997
405. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccineProceedings of the National Academy of Sciences · 1997
406. Route of Immunization and the Therapeutic Impact of Recombinant Anticancer VaccinesJNCI Journal of the National Cancer Institute · 1997
407. Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 MelanomaThe Journal of Experimental Medicine · 1997
408. Immunobiology of Human Melanoma Antigens MART-1 and gp100 and their Use for Immuno-Gene TherapyInternational Reviews of Immunology · 1997
409. Cloning and Characterization of the Genes Encoding the Murine Homoloties of the Human Melanoma Antigens MARTI and gp100Journal of Immunotherapy · 1997
410. Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T LymphocytesThe Journal of Experimental Medicine · 1996
411. Development of Cancer Immunotherapies Based on Identification of the Genes Encoding Cancer Regression AntigensJNCI Journal of the National Cancer Institute · 1996
412. Human tumor antigens recognized by T lymphocytes: implications for cancer therapyJournal of Leukocyte Biology · 1996
413. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residuesThe Journal of Immunology · 1996
414. RANTES Secretion by Gene-Modified Tumor Cells Results in Loss of Tumorigenicity In Vivo: Role of Immune Cell SubpopulationsHuman Gene Therapy · 1996
415. Improved Gene Transfer into Human Lymphocytes Using Retroviruses with the Gibbon Ape Leukemia Virus EnvelopeHuman Gene Therapy · 1996
416. Analysis of Expression of the Melanoma-Associated Antigens MART-1 and gp lOO in Metastatic Melanoma Cell Lines and in In Situ LesionsJournal of Immunotherapy · 1996
417. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.The Journal of Experimental Medicine · 1996
418. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expressionThe Journal of Immunology · 1996
419. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.The Journal of Experimental Medicine · 1996
420. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.The Journal of Experimental Medicine · 1996
421. Growth of tumor‐infiltrating lymphocytes from human solid cancers: Summary of a 5‐year experienceInternational Journal of Cancer · 1996
422. Secrecy in Medical ResearchNew England Journal of Medicine · 1996
423. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.Journal of Clinical Oncology · 1996
424. The Immunotherapy of Solid Cancers Based on Cloning the Genes Encoding Tumor-Rejection AntigensAnnual Review of Medicine · 1996
425. Vitiligo in Patients with MelanomaJournal of Immunotherapy · 1996
426. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapyThe Journal of Immunology · 1996
427. Combination Therapy with Interferon-γ and Interleukin-2 for the Treatment of Metastatic MelanomaJournal of Immunotherapy · 1996
428. Human Melanoma Antigens Recognized by T Lymphocytes.The Keio Journal of Medicine · 1996
429. Thyroid Dysfunction in 281 Patients with Metastatic Melanoma or Renal Carcinoma Treated with Interleukin-2 AloneJournal of Immunotherapy · 1995
430. T Lymphocyte-Directed Gene Therapy for ADA ⁻ SCID: Initial Trial Results After 4 YearsScience · 1995
431. Anti-Tumor Activity of Cytotoxic T Lymphocytes Elicited with Recombinant and Synthetic Forms of a Model Tumor-Associated AntigenJournal of Immunotherapy · 1995
432. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanomaCancer · 1995
433. Analysis of Cytokine Secretion by Melanoma-Specific CD4 ⁺ T LymphocytesJournal of Interferon & Cytokine Research · 1995
434. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytesThe Journal of Immunology · 1995
435. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes.The Journal of Immunology · 1995
436. Antigen processing in vivo and the elicitation of primary CTL responses.The Journal of Immunology · 1995
437. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.The Journal of Immunology · 1995
438. Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL.The Journal of Immunology · 1995
439. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.Journal of Clinical Oncology · 1995
440. Defective Major Histocompatibility Complex Class I Expression in a Sarcomatoid Renal Cell Carcinoma Cell LineJournal of Immunotherapy · 1995
441. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.The Journal of Immunology · 1995
442. The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinomaCancer · 1995
443. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes.The Journal of Experimental Medicine · 1995
444. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.Journal of Clinical Oncology · 1995
445. Helper T Cells Infiltrating Human Renal Cell Carcinomas Have the Phenotype of Activated Memory-Like T LymphocytesJournal of Immunotherapy · 1995
446. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.The Journal of Immunology · 1995
447. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinomaCancer · 1994
448. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.Proceedings of the National Academy of Sciences · 1994
449. Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2JNCI Journal of the National Cancer Institute · 1994
450. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.Proceedings of the National Academy of Sciences · 1994